<div id="readability-page-1"><p>Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report)'s stock price shot up 3.5% during mid-day trading on Tuesday . The stock traded as high as $21.63 and last traded at $21.9690. 80,512 shares changed hands during trading, a decline of 99% from the average session volume of 5,986,445 shares. The stock had previously closed at $21.23.</p><div><p><span></span><span>Get <strong>Sarepta Therapeutics</strong> alerts:</span></p></div><h2>Analyst Upgrades and Downgrades</h2><ul><li>Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside</li></ul><p>SRPT has been the topic of a number of research analyst reports. Wall Street Zen downgraded shares of Sarepta Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, November 8th. Bank of America boosted their price target on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the company an &#34;underperform&#34; rating in a report on Wednesday, October 22nd. BMO Capital Markets raised Sarepta Therapeutics from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and set a $50.00 target price on the stock in a research report on Monday, September 22nd. Guggenheim lowered their price target on Sarepta Therapeutics from $22.00 to $19.00 and set a &#34;buy&#34; rating for the company in a research note on Wednesday, November 5th. Finally, Leerink Partners raised their price objective on shares of Sarepta Therapeutics from $12.00 to $15.00 and gave the company a &#34;market perform&#34; rating in a research report on Tuesday, September 9th. Nine analysts have rated the stock with a Buy rating, fifteen have issued  a Hold rating and six have assigned  a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of &#34;Hold&#34; and an average price target of $33.68.</p><p><b>Check Out Our Latest Stock Analysis on SRPT</b></p><h2>Sarepta Therapeutics Trading Up 3.1%</h2><ul><li>Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences</li></ul><p>The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.79 and a current ratio of 2.95. The business's 50 day moving average price is $20.74 and its 200-day moving average price is $20.14. The company has a market cap of $2.29 billion, a price-to-earnings ratio of -7.29 and a beta of 0.54. </p><p>Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.15). The company had revenue of $399.36 million during the quarter, compared to analyst estimates of $331.51 million. Sarepta Therapeutics had a negative net margin of 11.25% and a negative return on equity of 4.85%. Sarepta Therapeutics's quarterly revenue was down 14.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.62 EPS.  On average, research analysts forecast that  Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year. </p><h2>Insider Buying and Selling</h2><ul><li>Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore</li></ul><p>In other Sarepta Therapeutics news, COO Ian Michael Estepan sold 13,187 shares of the stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total value of $294,201.97. Following the transaction, the chief operating officer owned 193,300 shares of the company's stock, valued at approximately $4,312,523. This represents a 6.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own  7.60% of the company's stock. </p><h2>Hedge Funds Weigh In On Sarepta Therapeutics</h2><p>Several large investors have recently modified their holdings of the stock. iSAM Funds UK Ltd acquired a new position in  Sarepta Therapeutics in the 3rd quarter valued at about $25,000.  Ancora Advisors LLC grew its position in shares of  Sarepta Therapeutics by 200.0% in the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 1,000 shares during the last quarter.  Byrne Asset Management LLC acquired a new position in  Sarepta Therapeutics during the 3rd quarter worth approximately $33,000.  Allworth Financial LP lifted its stake in  Sarepta Therapeutics by 2,098.8% in the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 1,721 shares during the last quarter.  Finally, Parallel Advisors LLC boosted its position in  Sarepta Therapeutics by 165.3% in the third quarter. Parallel Advisors LLC now owns 2,016 shares of the biotechnology company's stock valued at $39,000 after buying an additional 1,256 shares in the last quarter. 86.68% of the stock is owned by institutional investors. </p><h2>Sarepta Therapeutics Company Profile</h2> (Get Free Report)<p>Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta's core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company's mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.  </p><p>Sarepta's commercial products include several exon-skipping therapies approved by the U.S.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Sarepta Therapeutics</li><li>Do not delete, read immediately</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>Elon Warns “America Is Broke”. Trump’s Plan Inside.</li><li>Can Any Expenses Be Deducted From Capital Gains Tax?</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Sarepta Therapeutics Right Now?</h2><p>Before you consider Sarepta Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sarepta Therapeutics wasn't on the list.</p><p>While Sarepta Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SRPT

<p>Sarepta Therapeutics (NASDAQ:SRPT) stock rose 3.5% during mid-day trading, reaching $21.9690. Despite the rise, trading volume was significantly lower than average. Analysts have mixed ratings, with a consensus "Hold" and an average price target of $33.68. Recent insider selling and hedge fund activity were noted. The company reported a quarterly revenue decline and a negative EPS, missing estimates. Sarepta focuses on genetic medicines development.</p>

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 3.5% - Here's What Happened